Rash from newer cancer agents: why do we still not have effective therapy for palliation and/or prevention?
Butts
Matthew
M
Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Jatoi
Aminah
A
D000970:Antineoplastic Agents / Q000009:adverse effects*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005076:Exanthema / Q000139:chemically induced* / Q000517:prevention & control; D006801:Humans; D010166:Palliative Care
D000970:Antineoplastic Agents; D066246:ErbB Receptors
Clin Cancer Res. 2007 Jul 1;13(13):3913-21
17606725
J Clin Oncol. 2010 Mar 10;28(8):1351-7
20142600